Aprotinin, a hemostatic agent that inhibits the fibrinolyticenzyme plasmin,1 was approved by the Food and Drug Administration(FDA) in 1993 for reducing blood loss during coronary-arterybypass grafting (CABG). By 2006, aprotinin was prescribed forapproximately 200,000 patients undergoing cardiac surgery worldwide.2Aminocaproic acid and tranexamic acid are lysine analogues thatinhibit the binding of fibrin to plasminogen and also reduceblood loss, but a specific indication for bypass grafting isnot included on their labels.1 The safety of aprotinin was calledinto question in 2006 and 2007, when the results of an internationalcohort study by Mangano et . . . [Full Text of this Article]
Source Information
From the Vanderbilt Center for Education and Research on Therapeutics, Department of Preventive Medicine, Vanderbilt University School of Medicine and the Geriatric Research, Education, and Clinical Center, Nashville Veterans Affairs Medical Center — both in Nashville.
This article has been cited by other articles:
Martin, K., Wiesner, G., Breuer, T., Lange, R., Tassani, P.
(2008). The Risks of Aprotinin and Tranexamic Acid in Cardiac Surgery: A One-Year Follow-Up of 1188 Consecutive Patients. Anesth. Analg.
107: 1783-1790
[Abstract][Full Text]
Dietrich, W., Spannagl, M., Boehm, J., Hauner, K., Braun, S., Schuster, T., Busley, R.
(2008). Tranexamic Acid and Aprotinin in Primary Cardiac Operations: An Analysis of 220 Cardiac Surgical Patients Treated with Tranexamic Acid or Aprotinin. Anesth. Analg.
107: 1469-1478
[Abstract][Full Text]
Ray, W. A., Stein, C. M.
(2008). The Aprotinin Story -- Is BART the Final Chapter?. NEJM
358: 2398-2400
[Full Text]